Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Current Deferred Revenue (2022 - 2025)

Stoke Therapeutics has reported Current Deferred Revenue over the past 4 years, most recently at $11.9 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 37.33% year-over-year to $11.9 million; the TTM value through Dec 2025 reached $11.9 million, down 37.33%, while the annual FY2025 figure was $11.9 million, 37.33% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $11.9 million at Stoke Therapeutics, up from $5.8 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $31.6 million in Q3 2024 and troughed at $5.8 million in Q3 2025.
  • A 4-year average of $14.7 million and a median of $13.1 million in 2022 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 261.9% in 2024 and later tumbled 81.77% in 2025.
  • Year by year, Current Deferred Revenue stood at $14.9 million in 2022, then grew by 2.88% to $15.3 million in 2023, then grew by 24.05% to $19.0 million in 2024, then tumbled by 37.33% to $11.9 million in 2025.
  • Business Quant data shows Current Deferred Revenue for STOK at $11.9 million in Q4 2025, $5.8 million in Q3 2025, and $8.7 million in Q2 2025.